Podcasts about Prostate cancer

This week, we present an inspiring episode for anyone interested in the history, present, and future of prostate cancer care. In this Legends in Urology installment of the BackTable Urology Podcast, Dr. Gerald Andriole joins guest host Dr. Niraj Badhiwala to reflect on a career that has left a lasting impact on the field. --- SYNPOSIS Dr. Andriole shares personal stories from his upbringing in Northeastern Pennsylvania and his journey into medicine. He reflects on his expedited education through Penn State and Jefferson Medical College and his path to urology. He discusses his pivotal work in prostate cancer screening, including the influence of major trials like The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and traces the evolution of surgical and diagnostic techniques. The conversation also touches on current innovations and the future of prostate cancer management, offering valuable advice for the next generation of urologists. --- TIMESTAMPS 00:00 - Introduction01:59 - From Childhood to Medical School06:48 - Discovering Urology16:52 - Pioneering Prostate Cancer Screening24:07 - The PLCO Study: Design and Challenges28:57 - Controversies and Criticisms in Prostate Cancer Screening33:29 - Evolving Practices in Prostate Cancer Management44:19 - Future of Prostate Cancer Treatment

Josh's Guests: Sylvie Beljanski - author, Winning the War on Cancer Use the formulas used by French President Francois Mitterrand to successfully treat his advanced Prostate Cancer. Based on the scientific research of Mirko Beljanski, PhD, one of the first green molecular biologists Jason & Kristina Walker - farmers, ranchers, Starwalker Farms 7000 acres of Regenerative, Organic, Beef, Pork & Chicken raised in Northern California. Why the Beef, Pork, and Chicken taste better, contains more food value and is better for the environment Brenda Snow - author, Diagnosed the Essential Guide to Navigating the Patient Journey Find the resources you need for a successful outcome find us at: www.HeresToYourHealthWithJoshuaLane.com  

In our latest episode, host Michelle Dawes Birt and special guest Kipper Jones as they dive into their personal healing journeys. From navigating chronic pain to overcoming health challenges, they share inspiring stories and insights that can empower you to prioritize your well-being.  Kipper Jones developed his musical skills as a teenager working at Motown, absorbing the nuances of songwriting and production. This early experience laid the foundation for his own successful career as a hitmaker. Special thanks to Kipper Jones for sharing his incredible journey and insights into prioritizing your well-being.  Don't let fear hold you back—tune in now and discover how to embrace life more abundantly! Are you subscribed to the podcast? If not, make sure to subscribe so you never miss an episode. Please remember to rate, comment, share, and download your favorite episodes.  Connect with Real Chicks Rock!  Instagram - https://www.instagram.com/realchicksrock  Facebook - https://www.facebook.com/RealChicksRock1  Twitter - https://twitter.com/RealChicksRock1  Website: www.RealChicksRock.com  Connect with Kipper Jones:  Instagram: https://www.instagram.com/kipperjones #RealChicksRock #RealDiscussions #KipperJones #HealingJourney #HealthAwareness #ChronicPain #HipReplacement #Music #MusicJourney #Atlanta #LosAngeles #Empowerment #Inspiration #Podcast #Singer #Songwriter #Musicians #Creativity #BlackExcellence #MusicMatters #YouTube #YouTuber #YoutubeChannel #YouTubeVideo   I DO NOT OWN ANY MUSIC IN THIS VIDEO! [MUSIC & COPYRIGHT PERMISSION WAS GRANTED BY KEVIN HYMAN FOR KEMIT MUZIK, LLC FOR SONG WE STILL RISE (THE LOUNGE LIZARDS BOOTLEG MIX) ] THE MUSIC IS FOR PROMOTIONAL USE ONLY.

Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

SYLVIE BELJANSKI, author, WINNING THE WAR ON CANCER, use the formulas used by French President Francois Mitterrand to successfully treat his advanced Prostate Cancer based on the scientific research of Mirko Beljanski, PhD, one of the first green molecular biologists     JASON & CHRISTINA WALKER, farmers, ranchers, SKYWALKER FARMS  7000 acres of Regenerative, Organic Beef, Pork & Chicken raised in Northern California Why the Beef, Pork, and Chicken taste better, contains more food value and is better for the environment     BRENDA SNOW, author, DIAGNOSED The Essential Guide to Navigating the Patient Journey find the resources you need for a successful outcome

Recorded for release w/c 16th June 2025 This week Sophie-Rose Emery tells us about the Bat out of Hell tour arriving in her hometown at the Wolverhampton Grand, we get travel tips from Race Across the World winner Alfie Watts, Riviera Travel let us know about their amazing destinations, we find out about a Prostate Cancer screening night at AFC Wulfrunians and have music from MÆVEY.  

In this powerful episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with Dr. Preston Sprenkle, leading urologic oncologist at Yale School of Medicine, to explore the emerging role of focal therapy in prostate cancer care. A pioneer in MRI-ultrasound fusion biopsy using the Artemis Device, Dr. Sprenkle shares how focal treatments can offer cancer control while preserving quality of life.Whether you're on active surveillance or facing a Gleason 7 or 8 diagnosis, this episode helps you better understand:When focal therapy is appropriate—and when it's notKey differences between cryoablation, IRE (NanoKnife), and Tulsa Pro How patient goals (erectile function, continence, cancer control) shape treatmentWhat recent research shows about focal therapy success ratesHow to approach higher-risk prostate cancer (Gleason 8–10) with focal therapyWhat to know about PSMA PET scans, genomic tests, and repeat biopsiesThe real risks of skipping follow-up on active surveillanceYou'll also hear candid reflections on the evolution of holistic and integrative urology, and why building trust with your urologist matters more than ever.

In "Episode 6" of the series on "Present and future of diagnostics in prostate cancer", Assoc. Prof. Pawel Rajwa (PL) speaks with Prof. Peter Carroll (US) about the shifting landscape of active surveillance for intermediate-risk prostate cancer.Traditionally reserved for low-risk cases, active surveillance is now being considered for select patients with grade group 2 disease - especially when diagnosed through advanced techniques like MRI-targeted biopsy.Prof. Carroll explains how MRI has changed both the decision-making process and the biopsy approach, helping identify candidates with low risk of progression. The conversation addresses the potential to reduce overtreatment, minimise invasive follow-ups, and improve quality of life without compromising outcomes. Together, they examine how emerging data and imaging innovations are informing a more nuanced, patient-specific approach to prostate cancer care.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Welcome to this week's episode of our podcast, where we delve into an important and often discussed topic in men's health—prostate cancer. Today, we'll explore the latest insights into how prostate cancer is diagnosed and treated, providing valuable information for both patients and healthcare providers. A key focus will be on the role of PSA testing, its benefits, limitations, and how it fits into the broader screening and diagnostic process. Joining us as our expert guest is Dr. Brian Miles, a renowned specialist in urology and prostate health. With his expertise, we aim to shed light on current advancements, best practices, and emerging trends in prostate cancer management. Whether you've just been diagnosed, are due for screening, or simply want to stay informed, this episode offers essential knowledge to help you navigate this important health topic. Stay tuned!Where to find Dr. Joe Galati and his team:Dr. Galati's newsletter sign-upMedical Practice: Liver Specialists of TexasDr. Galati's Book Site: Eating Yourself SickFacebook: Dr. Joe GalatiDr. Galati's YouTube ChannelPlease send feedback and suggestion. You can message me here. Hosted on Acast. See acast.com/privacy for more information.

Prostate cancer is on the rise in India, posing not just medical but also financial challenges. Low awareness, stigma around the symptoms and the potentially high cost of treatment are serious concerns. If you are over 45 years of age or have a family history of prostate cancer, make sure you consult your doctor and get regular checkups. If caught early, prostate cancer is curable. Please listen to the latest episode of All Indians Matter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Shiksha Gallow currently serves as the Medical Director of the Holistic Integrative Healing Institute and is notably the first and only South African to sit on the Board of Directors of the Society of Cannabis Clinicians. Dr. Gallow's passion lies in leveraging her medical and scientific expertise to develop Active Pharmaceutical Ingredients (APIs) from cannabis and other plant species to treat various conditions. She has achieved significant success in treating patients with autoimmune diseases and cancer, and she strongly advocates for patient access to safe and effective medicines that improve quality of life. At CannMed 25 she will present “Comprehensive Evaluation of the ‘Impact of Cannabinoids' on Prostate Cancer: Integrating PSA, PET/CT Scans and Patient-Related Outcomes”  During our conversation we discuss The variety of treatment options for prostate cancer and the role of cannabinoids may play Results from an empirical study that evaluated how cannabinoid treamtment impacts PSA levels PET/CT scans and patient reported outcomes  How patients were selected and grouped for the study  Future research opportunities  and more  Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico.  With over 500,000 square feet of STATE OF THE ART facilities, Prich uses  the highest standards of agricultural and manufacturing practices to Guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com.  Additional Resources Dr. Gallow on Linkedin Holistic Healing Dr Gallow (Facebook) CannMed Video Archives

AUA2025: AUA Guidelines on Early Detection of Prostate Cancer: Maximizing Benefits, Minimizing Harm CME Available: https://auau.auanet.org/node/43021 At the conclusion of this activity, participants will be able to: 1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement. 2. Maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers. 3. Describe the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences. 4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used. 5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Real Housewives of Atlanta fans, this one's for you - Former RHOA star, Dwight Eubanks, has shared some shocking news about his battle with prostate cancer, and we're breaking it all down this week on Medical Mondays. We'll talk about the myths, the facts, and what every man (and the people who care about them) needs to know about early detection.But that's not all. Abby Lee Miller from Dance Moms is making headlines again with claims that medical negligence left a catheter in her abdomen for FOUR years after the surgery. How does something like this happen, and what can we do to protect ourselves from medical errors? Trust, this is a conversation you don't want to miss.We're also addressing the frightening story of a woman who died from a brain-eating amoeba after using tap water for a nasal rinse. Plus, Sinbad's incredible return to acting after his stroke, and the inspiring resilience behind his recovery journey.This episode isn't just about headlines, it's about your health, your advocacy, and staying informed.This podcast is intended to be informational only.  It is not a medical consultation, nor is it personalized medical advice.  For medical advice, please consult your physician.#HealthHappyLifePodcast #DrFrita #MedicalMondays #MedicineInTheNewsHere are a few helpful resources to help on your journey to wellness:▶️ Subscribe so you will never miss a YouTube video.

According to the American Cancer Society, approximately one in eight men will be diagnosed with a prostate condition during their lifetime. Focused ultrasound offers a noninvasive, radiation-free treatment option for prostate conditions and has been approved in more than 50 countries, including the United States. In this episode of Curing with Sound, we explore focused ultrasound for prostate cancer through the lens of a patient and a patient advocate. Bob Palmer, who underwent the TULSA-PRO procedure—a minimally invasive, incision-free focused ultrasound treatment—discusses his decision-making process and treatment experience. He is joined by Eve Satterthwaite, a registered nurse and patient educator at Profound Medical. She provides an overview of what patients can expect from the procedure and her role in guiding them through treatment. Bob shares how Eve helped him evaluate treatment options after his prostate cancer diagnosis and what led him to choose focused ultrasound, particularly in light of potential side effects associated with surgery and radiation. Eve explains how she helps patients understand their options, outlines the clinical benefits of the TULSA procedure, and addresses common patient concerns. Discussion highlights: Modern Prostate Treatment Options – An overview of the TULSA-PRO procedure, an FDA-approved focused ultrasound treatment that offers an incision-free alternative to traditional prostate cancer treatments, with minimal downtime and reduced risk of side effects affecting quality of life. Informed Choices Through Education – Insights into how clear, comprehensive information about available treatments can help patients make confident, well-informed decisions. All patient stories featured on the Curing with Sound podcast are personal accounts of an individual's experience with focused ultrasound treatment. Please be aware that each patient's situation is unique, and outcomes may vary. The information provided in this story should not be considered as medical advice or a guarantee of specific results. It is important to consult with a qualified healthcare provider to discuss your condition and determine the best treatment options for you. The Focused Ultrasound Foundation does not endorse any specific treatment or medical procedure and encourages all patients to seek professional medical guidance tailored to their individual needs. Visit TULSAprocedure.com for more information EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

In this episode of The Common Sense MD, Dr. Tom Rogers dives deep into one of the most debated topics in men's health: PSA screening for prostate cancer. June is Men's Health Month, and Dr. Rogers uses this timely opportunity to address widespread confusion and anxiety surrounding PSA (prostate-specific antigen) testing.Drawing from recent headlines—including the news about Joe Biden's missed prostate cancer diagnosis—Dr. Rogers explores why prostate cancer screening is so controversial, the shortcomings of current medical recommendations, and the risks of both over- and under-testing. He explains who should get screened and when, discusses the nuances of PSA interpretation, and highlights the importance of being your own health advocate.Listeners will also learn practical tips for getting accurate PSA test results, the value of baseline screenings, the role of digital rectal exams, and the importance of monitoring PSA velocity and free PSA percentage. Dr. Rogers demystifies what PSA numbers mean, touches on advanced testing options, and reminds men not to panic if their PSA is elevated—instead, emphasizing thoughtful follow-up and individualized care.Whether you're confused about screening guidelines, worried about your own results, or simply want to be proactive about your health, this episode provides clear, common-sense advice rooted in real-world medical experience. Tune in to get the facts on prostate health, advocate for yourself, and make the most informed decisions possible.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine

52:10- Lt. Col. Chuck DeVore (Ret.), Chief National Initiatives Officer at the Texas Public Policy Foundation who served as a Republican member of the California State Assembly from 2004 to 2010 Topic: "Trump moves fast to save LA from a 1992 repeat" (Fox News op ed) 1:02:25- Dr. Gil Lederman, Expert in Prostate Cancer and the host of "Radiosurgery New York with Dr. Gil Lederman" on AM 970 The Answer Topic: Biden's prostate cancer prognosis 1:12:30- Dr. Marc Siegel, physician, Professor of Medicine at the NYU Langone Medical Center, author, and contributor to Fox News Topic: "Grandma and Grandpa are turning golden years into a high time and it’s not safe" (Fox News op ed) 1:25:19- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Miguel Uribe assassination attempt, other news of the day 1:32:31- Nicole Parker, Special Agent with the FBI from 2010 through October 2022 and a Fox News contributor Topic: FBI involvement in the Los Angeles protests 1:49:06- Rich Lowry, Editor of the National Review and the author of "The Case for Nationalism" Topic: "Biden WH flack Karine Jean-Pierre’s latest ruse just moves her from one ‘grift’ to another" (New York Post op ed) 2:01:56- Thomas Homan, Border Czar for the Trump administration Topic: Los Angeles protestsSee omnystudio.com/listener for privacy information.

Phillip's Fit Vegan Comeback After Prostate Cancer | Fit Vegan Podcast Ep. #388Join our Free Fit Vegan weekly newsletter: https://fit-vegan-coaching.kit.com/newsletterInterested in working with our world class team, Book your application call here: http://book.fitvegancoaching.com/podcastWelcome to the Fit Vegan Podcast! In this episode of the Fit Vegan Podcast, Coach Nick chats with Philip, a Fit Vegan athlete, about his inspiring four-month transformation. Philip shares how he moved from injury-prone CrossFitter to thriving on a hybrid program combining CrossFit, strength training, and mobility work. By dialing in his macros and switching to a whole food plant-based diet, he also improved his PSA levels and reduced prostate cancer risks. He credits consistency, discipline, and the supportive Fit Vegan community for his progress in mindset, fitness, and overall health.In This Episode, We Cover: [00:00–12:42] Philip's Inspiring Transformation After 50, Overcoming Fitness Setbacks, And Finding The Right Routine For Lasting Health.[12:43-23:39] Why Support And Structure Matter—How Accountability And A Balanced Training Approach Can Make All The Difference.[23:40-27:30] Boosting Heart Health, Recovering Smarter, And Learning To Thrive With A New, Sustainable Workout Rhythm.[27:31-36:15] Consistency Over Time, Life Lessons From Fitness, And How Discipline Brings Both Physical And Emotional Rewards.[36:16-50:50] Becoming A Role Model, Managing Health Risks, The Value Of Expert Guidance, And Looking Ahead With Confidence.Key Quotes“ I'm working out, but not laying in a puddle of sweat.” -Phillip.“ What does intensity look like? Like what does a hard workout look like?”-Coach Nick.My name is Maxime Sigouin. I am the founder of Fit Vegan Coaching and Empire Builders Agency. I have a passion for serving and helping people live to their fullest potential.Book Your FREE Consultation Call Here: http://book.fitvegancoaching.com/podcast- Follow me on Instagram: https://www.instagram.com/maximesigouinofficial/- Join our FREE Fit Vegan Community: www.freefitvegancommunity.com- Youtube Channel : https://linktw.in/AyNrSW

Keeping the Prostate healthy is important as men age.  Prostate Cancer is the #1 Cancer in Men, which includes "almost all men over the age of 80".  In this episode, you'll discover:—How keeping your Testosterone levels up can help prevent Prostate Cancer.  And why Dr. Prather believes men don't "completely function well" outside of Prostate numbers in the 800-900 range. —The Benign Prostatic Hypertrophy (BPH) condition that creates an enlargement of the Prostate and is caused by Estrogen dominance. —The reason Dr. Prather was not surprised to hear that former President Joe Biden had Prostate Cancer.  And why he would not be surprised if President Donald Trump has it, too. —Why Diet, particularly increased Fiber, and Exercise are so important for Prostate Health.  And why it's important to eliminate toxins like heavy metals, infections, and parasites that can kick off Cancer in the body.—How a Native American herbal formula first developed by Hiawatha is still used by Dr. Prather for his patients to help detox the body.  And why Dr. Prather says that it's something "almost everyone who has Cancer should be taking".—The Vitamins, Minerals, Herbals, and Homeopathics that are most helpful for Prostate health and for lowering side-effects from Chemotherapy.  And how the Prostate contains the highest concentration of Zinc in the human body and is "critical" for Prostate health.—Why Dr. Prather predicts this generation of young men will have increased rates of Prostate Cancer due to Marijuana use. —The instantaneous relief Acupuncture provides for those suffering from Prostatitis.  And why you shouldn't be afraid of where Dr. Prather puts the needles! —The amazing story of a terminal Prostate Cancer patient sent by his oncologist to Dr. Prather for pain relief through Acupuncture.  And why the oncologist called to ask what Dr. Prather was doing to the patient after seeing the patient's PSA numbers plummet. —How just preventing a patient from becoming Anemic during Cancer treatment can increase their survival chances by 50%.  And how keeping the Liver clean during Cancer treatment can increase their chance of survival by another 25%.http://www.TheVoiceOfHealthRadio.com

In "Episode 5" of the series on "Present and future of diagnostics in prostate cancer," Assoc. Prof. Henkjan Huisman (NL) and Dr. Alexander Ng (GB) discuss the exciting, yet controversial topic of artificial intelligence (AI) in prostate cancer diagnosis.They examine where AI currently stands in the diagnostic pathway, including its role alongside MRI-guided biopsies. The discussion covers the progress AI has made in improving accuracy and efficiency in detecting prostate cancer, while also addressing the limitations and challenges that still exist.The episode raises important questions about whether AI is truly transformative or if the excitement around it is just hype, offering a balanced view on its present and future impact in prostate cancer diagnostics.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Picking up from Episode 23, your hosts turn their focus to the highly anticipated prostate cancer presentations from the 2025 ASCO Annual Meeting in Chicago. They begin with a discussion on mCSPC, focusing on the AMPLITUDE trial, followed by results from TALAPRO-2, the ARANOTE trial, IRONMAN, and STAMPEDE. The episode wraps with key abstracts and oral presentations on mCRPC.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

A big welcome back to EAU Guideline gurus, Dr Derya Tilki (Martini-Klinik, Hamburg, Germany), and Dr Gianluca Giannarini (Santa Maria della Misericordia University Hospital, Udine, Italy), for an overview of the major headlines from this year's EAU Guideline update. Derya is Deputy Chair of the EAU Prostate Cancer Guideline Committee and has picked out four areas to discuss. These are: 1. New stratification for favourable and unfavourable prostate cancer2. PSMA PET/CT now recommended for unfavourable intermediate-risk cancer3. No change to PLND recommendations due to lack of benefit in MSKCC RCT update4. Importance of multidisciplinary approach for mHSPCSo tune in so you can pretend you have read the full 250 page 2025 Guideline!! Your usual co-hosts are Professor Declan Murphy and Dr Renu Eapen.Even better on our Youtube channelLinks:Updated 2025 EAU Prostate Cancer Guideline 

BUFFALO, NY - June 4, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells." In this study, authors Shan Lu and Zhongyun Dong from the University of Cincinnati College of Medicine investigated how interfering with a protein interaction could reduce prostate cancer growth. Their study based on prostate cancer cells shows that blocking the link between PCNA, a protein important for DNA repair, and the androgen receptor (AR), which drives prostate cancer growth, can slow down cancer cell multiplication. This discovery could lead to a new treatment for patients with advanced prostate cancer, particularly those no longer responding to hormone therapy. Prostate cancer is one of the most common cancers in men. Many patients eventually become resistant to hormone treatment. In this advanced stage, called castration-resistant prostate cancer (CRPC), tumors continue to grow by using either the full-length androgen receptor (AR-FL) or altered versions called AR variants (AR-Vs). This study shows that the interaction between AR and PCNA helps both AR-FL and AR-Vs remain active, supporting cancer cell survival and growth. The researchers identified a new region in the AR that binds to PCNA. They developed a small peptide, R9-AR-PIP, to mimic this region and block the AR-PCNA connection. They found that this peptide reduced AR's ability to bind DNA and lowered the levels of key genes involved in cancer cell growth. Importantly, the peptide was effective against both types of AR, including the variant forms that are especially challenging in CRPC. “We identified a second PIP-box (PIP-box592) in the DNA binding domain of AR and found that dihydrotestosterone enhances the binding of full-length AR (AR-FL) but not a constitutively active variant (AR-V7) to PCNA.” They also tested a small molecule, PCNA-I1S, which interferes with PCNA's ability to move to the cell nucleus and interact with AR. This molecule showed similar effects as the peptide, reducing AR activity and stopping cancer cell growth. Together, these findings suggest that targeting PCNA/AR interactions could be a promising strategy to fight CRPC, especially in patients with limited treatment options. One key result was that both the peptide and the small molecule reduced the levels of cyclin A2, a protein that helps cells divide and is often overexpressed in CRPC. Since this protein is linked to patients' poor outcomes, its reduction could be especially beneficial. This study improves our understanding of how prostate cancer continues to grow even after hormone treatments fail. By blocking a crucial helper of the androgen receptor, researchers have uncovered a new way to potentially slow or stop the disease. Further studies in animal models are needed, but this approach could lead to more effective treatments for men with advanced prostate cancer. DOI - https://doi.org/10.18632/oncotarget.28722 Correspondence to - Zhongyun Dong - dongzu@ucmail.uc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28722 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Today's programme is all about prostate cancer; exploring what the disease is, who gets it, and how it can be treated. We'll explore the game-changing test from a Cambridge based firm, and question whether sometimes the best approach is to leave the cancer alone... Like this podcast? Please help us by supporting the Naked Scientists

Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics: Introduction (0:00) Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37) Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18) CME information and select publications

Dr. John Sweetenham shares highlights from Day 5 of the 2025 ASCO Annual Meeting, including data from large trials in advanced malignant melanoma and mCSPC plus a new approach to first-line treatment for patients with multiple myeloma who are not transplant eligible. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 5 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. The selected abstracts from this final day of ASCO25 include important new data from large, randomized trials in patients with advanced malignant melanoma and patients with metastatic castration-sensitive prostate cancer, as well as a new approach to the first-line treatment of patients with multiple myeloma who are not transplant eligible.  Starting with LBA9500, this study was conducted in patients with completely resected stage III or IV malignant melanoma and compared the combination of relatlimab plus nivolumab versus nivolumab alone in this population. The study, named the RELATIVITY-098 trial, was presented by Dr. Georgina Long from the University of Sydney, Australia. In her introduction to the study, Dr. Long explained that the current standard of care for adjuvant therapy of resected stage III/IV melanoma is with PD-1 monotherapy with nivolumab, but that about 50% of patients will suffer from a subsequent relapse. In the first-line setting in patients with advanced or unresectable melanoma, the combination of nivolumab with the LAG-3 inhibitor, relatlimab, has been previously shown to improve progression-free survival in the RELATIVITY-047 trial. The current study evaluated this same combination in the adjuvant setting. More than 1,000 patients from 24 countries were randomized to receive either nivolumab alone (546 patients) or the combination of nivolumab with relatlimab (547 patients). Both treatments were given for a maximum of 1 year or until progression of disease, unacceptable toxicity, withdrawal, or death. Various biomarker studies were also undertaken including LAG-3 and PD-1 expression on CD8-positive T cells. The primary endpoint of the study was relapse-free survival, and Dr. Long reported that this was the same in both arms of the study. For example, at 24 months, the relapse-free survival was 64% in the monotherapy arm compared with 62% in the combination arm. The hazard ratio was 1.01 and the P value was 0.928. Metastasis-free survival was also identical in both arms. No benefit was observed for the combination in any of the prespecified subgroups. No new toxicity signals emerged compared with the RELATIVITY-047 trial. Interestingly, the baseline surface expression of LAG-3 and co-expression of LAG-3 and PD-1 on CD8 T cells in the 098 adjuvant trial were lower than in the 047 advanced disease trial, perhaps explaining why the combination did not confer benefit over nivo alone in the adjuvant setting. This is an important result, demonstrating that results from one clinical setting cannot always be extrapolated to another. Although the combination has gained some use in the adjuvant setting, this study clearly demonstrates that more drug in this situation is no better and that monotherapy remains the current standard of care. Results from the AMPLITUDE trial for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes, in LBA5006, were presented today by Dr. Gerhardt Attard from University College London, UK. This international, multicenter study evaluated the combination of the selective PARP inhibitor, niraparib, in combination with abiraterone acetate and prednisone. The same combination has been previously shown to improve outcomes in castration-resistant metastatic prostate cancer harboring BRCA mutations in the MAGNITUDE study. The current trial included patients with castration-sensitive disease with HRR mutations including BRCA1/2. Six hundred and ninety-six patients were randomized between niraparib, abiraterone, and prednisone plus androgen deprivation therapy, or the same combination with placebo instead of niraparib. Permitted prior therapies included no more than 6 months of prior androgen deprivation therapy and the use of docetaxel, or prior palliative radiation therapy. The primary endpoint of the study was radiographic relapse-free survival. Dr. Attard reported that the risk for radiographic progression-free survival in the whole population was significantly reduced by 37% with niraparib and abiraterone acetate plus prednisone compared with the placebo arm. The radiographic progression-free survival risk reduction with niraparib in the prespecified BRCA1/2 subgroup was 48% and reached statistical significance compared with the placebo arm. The secondary endpoint of time to symptomatic progression was also improved with niraparib in the HRR population and the BRCA1/2 subgroup. There was a trend for overall survival favoring the niraparib combination. However, the overall survival data were immature at this first interim analysis and did not yet reach statistical significance. No new safety concerns emerged with the toxicity data consistent with the MAGNITUDE study. Less than 5% more of the patients on the experimental arm discontinued treatment in comparison to the control arm. The authors conclude that the AMPLITUDE study results support the use of niraparib, abiraterone, and prednisone as a new treatment option for patients with metastatic castration- sensitive prostate cancer and BRCA and homologous recombination repair gene alterations. The results certainly support this conclusion and are potentially practice-changing. Turning to hematologic malignancies, my final selection from today's presentations is Abstract 7504, presented by Dr. Hang Quach from St Vincent's Hospital, Melbourne, Australia, and describes a novel combination of elranatamab, daratumumab, and lenalidomide in patients with newly diagnosed multiple myeloma who are not transplant-eligible – the so-called MagnetisMM-6 trial part 1. Elranatamab is a novel bispecific T-cell engaging antibody directed against BCMA and CD3, which has previously been approved for certain patients with relapsed and refractory multiple myeloma. In the present study, this was combined with lenalidomide and daratumumab in newly diagnosed patients. The report today describes the dose-finding phase of this study, which was part 1, specifically addressing so-called dose level ‘G', comprising elranatamab 76mg subcutaneously every 4 weeks plus daratumumab 1800mg subcutaneously and lenalidomide 25mg given orally. Thirty-seven patients were entered at this dose level, of whom 32 were on treatment at the time of analysis. Early response data show an overall response rate of 97.3%. With median follow up of 7.9 months, the current CR rate is 27% with a VGPR rate of almost 68%. The most frequent toxicities were hematologic, with neutropenia observed in 75%. Some cytokine release syndrome was observed in about 60% of patients, but none was greater than grade 2. The authors conclude that this combination is active in untreated multiple myeloma, with manageable toxicity and evidence of responses which appear to deepen over time. The dose-finding component of this trial is continuing and will subsequently progress into a phase 3 trial based on the data from the current study. This will compare daratumumab plus lenalidomide with the same combination plus elranatamab in previously untreated patients. That concludes our special coverage from the 2025 ASCO Annual Meeting. Thanks for listening and we hope you have enjoyed listening to our top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

Dr Leonard G Gomella from the Sidney Kimmel Cancer Center in Philadelphia, Pennsylvania, Dr Evan Y Yu from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Daniel George from Duke Cancer Institute in Durham, North Carolina, discuss important clinical datasets and patient cases relevant to AKT inhibition in the care of patients with prostate cancer. CME information and select publications here.

Gary comments on several recent news items, hoping to bring a bit of sanity (and biblical worldview) to the cultural craziness. The Catholic Church, SPLC, Charlie Kirk, transgenderism, and track and field all get a bit of analysis from Gary. He even closes the episode with a bit of health advice. It has something for everyone!

Listen up men! Prostate cancer is a significant health concern for us guys. Right now it is ranking as the most commonly diagnosed cancer among men in the United States, excluding skin cancers. This year, in 2025, an estimated 313,780 new cases are expected to be diagnosed, and approximately 35,770 men are projected to die […] The post New Show: A Holistic Treatment For Prostate Cancer? The Promise of 4-Methylumbelliferone (4-MU) appeared first on Extreme Health Radio.

WOW! Tonight, we are honored to have on TV legend Dr. Drew! To start, we ask for his expertise on Joe Biden's “sudden” prostate cancer diagnosis. Did the former president HIDE that he had cancer? How long could he have had it? Dr. Drew shares his expert opinion as well as his own personal experience with prostate cancer. Following, we discuss Dr. Drew's most notorious guests on the show “Celebrity Rehab,” like Rodney King, Dennis Rodman, and Tom Sizemore. What celebrities today could benefit from “Celebrity Rehab”? We find out! Finally, we talk about other famous characters from the show “Teen Mom,” like Farrah Abraham and Amber Portwood. Don't miss this episode of “Prime Time with Alex Stein”!Today's Sponsors:'The Last Rodeo'"The Last Rodeo," from the creators of "The King of Kings" and "Sound of Freedom," is an emotional, action-packed story of a retired rodeo legend making one final ride to save his grandson. Filled with raw emotion and themes of healing and courage, this movie will tug at your heartstrings. Get your tickets today at Angel.com/ALEX before they sell out.WINNINGConservatives are gaining ground, and BlazeTV is at the forefront of the movement, providing a platform for bold voices and fearless commentary. With investigative journalism and original documentaries, BlazeTV offers content the mainstream media won't show you. Subscribe now at https://BlazeTV.com/ALEX using code PRIME TIME 99 to get your first 30 days for just 99 cents and join the fight for free speech and independent thought! Learn more about your ad choices. Visit megaphone.fm/adchoices

Radio show from May 29, 2025 Watch here: https://rumble.com/v6u1ycb-thinking-logically-radio-show-episode-206-how-long-has-biden-really-had-pro.html

One in eight men will be diagnosed with prostate cancer, and President Biden's recent diagnosis has many people asking: Am I at risk? Should I get screened? Dr. Sanjay Gupta breaks down what to know about PSA tests, family history, screening age, and how your diet might factor in.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

The news last week of former President Joe Biden's advanced prostate cancer has more people thinking and talking about the condition.About 1 in 8 men in the U.S. are diagnosed with prostate cancer at some point in their lives. It's the most-diagnosed cancer in men and the second-leading cause of cancer-related death in American men after lung cancer. That's according to the American Cancer Society.In this installment of our series, "In Good Health," we talk about how to detect and treat prostate cancer. Then, we switch gears to talk about the Food and Drug Administration's plans to potentially restrict access to the COVID-19 vaccine.Want to support 1A? Give to your local public radio station and subscribe to this podcast. Have questions? Connect with us. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Get the facts, without the spin. UNBIASED offers a clear, impartial recap of US news, including politics, elections, legal news, and more. Hosted by lawyer Jordan Berman, each episode provides a recap of current political events plus breakdowns of complex concepts—like constitutional rights, recent Supreme Court rulings, and new legislation—in an easy-to-understand way. No personal opinions, just the facts you need to stay informed on the daily news that matters. If you miss how journalism used to be, you're in the right place. In today's episode: Former President Biden Diagnosed with Prostate Cancer; Here's What His Diagnosis Means (1:17) Defense Dept. Officially Accepts Qatari Plane for Air Force One; Here's What the Refit Project May Cost (3:56) Trump Announces New 'Golden Dome' Missile Defense System (6:37) DOJ Drops Police Reform Agreements with Louisville and Minneapolis (9:24) Treasury Dept. to Stop Circulating Pennies by 2026 (14:43) Supreme Court Ties 4-4 in Religious Charter School Case; Here's What That Means (17:24) Boeing and Government Reached THIRD Agreement in 4 Years to Avoid 737 Max Trial; Will the Judge Accept It? (20:43) DHS Revokes Harvard's Ability to Enroll International Students; Court Intervenes (25:39) Make America Healthy Again Commission Releases First Health Report Per President's Orders (29:27) One Big Beautiful Bill Act; Here's What's In It (33:14) Quick Hitters: Lawmaker Indicted, EU Tariffs Postponed, Hegseth Puts Restrictions on Reporters, 500% Sanctions on Russian Oil Buyers, US Steel Partnership (46:35) SUBSCRIBE TO JORDAN'S FREE NEWSLETTER. Watch this episode on YouTube. Follow Jordan on Instagram and TikTok. All sources for this episode can be found here.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

On the next Charlotte Talks, we look at the treatment, screening and testing options for prostate cancer patients. We also look at promising new treatment research recently released by Duke University and hear from a prostate cancer survivor.

Doctors say aggressive forms of prostate cancer are difficult to catch. How can we improve screening protocols to prevent late stage diagnoses and improve survival rates?

Prostate cancer has been called the silent killer and it is the second most common form of cancer among males in the world. Yet, despite the fact that it only affects men, many are reluctant to talk about it. Following former president Joe Biden's announcement that he has an aggressive form of the disease, we hear from two men about their diagnosis, their fears, the stigma and the reality of dealing with side effects like erectile dysfunction and incontinence after surgery. Leslie, a 46-year old DJ in Britain, is black and he discusses why black men are at higher risk from the disease with an oncology specialist from Nairobi, Kenya. And, 65-year-old Guy Jenkins also has prostate cancer and his daughter, a pharmacist, is helping her father cope with the condition.

Dr Dawn Michael joins Stew to discuss famous Dilbert Cartoonist Scott Adam's' shocking announcement that he has turbo Prostate Cancer with only months to live - and vindicates anti-vaxxers! Christopher key joins Stew to discuss all the disturbing human experiments that the US Government and military conduct on the American people! And what to do to heal them Watch this new show NOW at https://StewPeters.com! Western civilization has been infected by a parasitic invasion of foreign ideals and values that have been introduced into our culture by strange and morally degenerate people whose goal is world domination. We have been OCCUPIED. Watch the film NOW! https://stewpeters.com/occupied/ Memorial Day Special: Freedom Isn't Free, But This Deal Almost Is!

On today's episode, Andy & DJ discuss Biden breaking his silence after revealing he's battling with aggressive prostate cancer, James Comey's weird social media approach landing him in hot water, and the video of the Indian version of the Titanic.

Welcome back to another episode of The Bold American Podcast. This week, Cons, Rob, and Ryan are back in full to discuss their last 72 (00:00-17:37). The Mexican Naval Ship crashing into the Brooklyn Bridge (17:38-20:47). President Biden's recent diagnosis of Prostate Cancer (20:48-28:30). Some conspiracy theory discussion (28:31-36:02). American Manhunt: Osama Bin Laden Documentary (36:03-41:13). Bruce Springsteen's recent comments on President Trump (41:14-49:32). Some recent updates in the trial of P Diddy (49:33-57:25). And we end the show with another round of Q&A from Rob and some Post-show discussion (57:26-01:21:25).You can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/ZeroBlog30

There are more mysteries than answers surrounding the Biden team. Why did Joe Biden's medical team announce right now—on the eve of the release of “Original Sin”—this shocking story that the president, who just left office 100 days ago, was suffering from a very seriously rare, malignant form of prostate cancer, asks Victor Davis Hanson on today's edition of “Victor Davis Hanson: In His Own Words:”   “President—he was vice president, he was president, now he's an ex-president. They are accorded the best, most comprehensive diagnostic medical care in the world. Isn't it true that Joe Biden would've known about this? We just had a report—right before he stepped down, in the summer of 2024—an exhaustive medical report, that he was fine. But he is trying to tell us, or sadly, his team is trying to tell us that, just in a matter of nine months, he developed a prostate cancer unknown to all of his doctors. Unknown—that didn't appear on any of his diagnostic tests.”

God's Debris: The Complete Works, Amazon https://tinyurl.com/GodsDebrisCompleteWorksFind my "extra" content on Locals: https://ScottAdams.Locals.comContent:Politics, Flying Cars, Home Depot Sales Spike, Mayor Brandon Johnson, Stephen Miller, America First Legal, NYS Grievance Committee, Letitia James, James Comey Sea Shells, President Trump, Biden's Note Cards, Biden's Teleprompter, Biden Aides Concealment Techniques, Kamala Harris, Biden's Prostate Cancer, Hakeem Jeffries, Laura Loomer, Harris Campaign Paid Endorsements, Rep. LaMonica McIver Assault Charges, Alina Habba, US Budget Debt Crisis, US Deficit Death Spiral, CBS President Resignation, Epstein Suicide Controversy, TPS Venezuelans, India Pakistan Conflict, OpenAI Co-Founder Doomsday Bunker, Spain Telecom Issues, China's Orbital Super Computer Satellites, Russian Economy, Ukraine's KRAMPUS, Robot Warfare, US Iran Nuclear Talks, Scott Adams~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure.

President Trump works the phones and gets what could be a breakthrough in Russia's war against Ukraine. According to Trump the two sides are ready to negotiate. Plus, brand new details on the Mexican training ship that hit the Brooklyn Bridge killing two people on the vessel.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

The former US president Joe Biden was diagnosed with prostate cancer on Friday after seeing a doctor for urinary symptoms. Also: Israel says it will allow "basic amount" of food into Gaza, ending 10-week blockade.

On today's episode, Liz Wheeler is joined live by Dr. Craig M. Wax, D.O., to discuss President Biden's announcement that he has colon cancer. Was this a massive, years-long medical cover-up? Did Biden have an obligation to tell the public sooner? Plus, Liz breaks down the true intent behind James Comey's "8647" post on Instagram. Tune in to find out his primary motivation for his now-deleted photo! SPONSORS: THE LAST RODEO: Tickets are going fast, so don't wait. Reserve your seats now for this powerful new film, in theaters starting May 23rd. Get your tickets today at https://Angel.com/LIZ HOME TITLE LOCK: Go to https://hometitlelock.com/lizwheeler and use promo code LIZ to get a FREE title history report so you can find out if you're already a victim AND 14 days of protection for FREE! And make sure to check out the Million Dollar TripleLock protection details when you get there! Exclusions apply. For details visit https://hometitlelock.com/warranty PREBORN: Your tax-deductible donation of twenty-eight dollars sponsors one ultrasound and doubles a baby's chance at life. How many babies can you save? Please donate your best gift today– just dial #250 and say the keyword, “BABY" or go to https://preborn.com/LIZ. BLAZETV: If you're ready to keep winning, shop your values and make sure we don't lose the ground we've gained—go to https://BlazeTV.com/liz and subscribe today. Use promo code LIZ, and you'll save 20 bucks right now off our annual plan. BlazeTV. Unfiltered. Unafraid. On Demand. Learn more about your ad choices. Visit megaphone.fm/adchoices

SEASON 3 EPISODE 127: COUNTDOWN WITH KEITH OLBERMANN A-Block (1:45) HEADLINE: BIDEN'S CANCER DIAGNOSIS: The concern here, obviously, is Joe Biden’s health and comfort. I know him enough, however, to believe that it has occurred to him that the timing of this terrible news carries with it one extraordinary irony. The car in which all of the Biden Acuity Truthers and Reporters and Book Writers and Finger Waggers has just stopped suddenly and they have all been ejected from the car they were climbing over each other in order to drive faster and faster. And you deserve it utterly, Jake Tapper and Alex Thompson and Jonathan Allen and Robert Hur and Politico and The Washington Post which yesterday MORNING printed a column that began “The verdict is in. Joe Biden is to blame.” (. ) SPECIAL COMMENT: TRUMP THREATENS SUPREME COURT. Trump has now descended to making threats against the Supreme Court. Under his own name? Indirectly and stochastically. Under the names of others whose menacing he re-posts? Directly. Directly. And specifically towards the justices HE himself appointed. This country is now in this frozen moment of madness in which its president isn’t just ignoring and trying to veto the judiciary and the Supreme Court, but actually encouraging violence against its members. Trump has also now amplified at least 14 posts demanding the arrest of former FBI Director James Comey, including one claiming Comey’s dumb photo proves the assassination attempt against Trump last year was quote “an inside job” and another calling for quote “public military tribunals” for President Obama – a post that was actually captioned “Re-truth if you want public military tribunals” which Trump… re-truthed. B-Block (34:20) THE WORST PERSONS IN THE WORLD: Trump thinks a soccer stadium in New York will be used in the L.A. Olympics. Somebody high up at Twitter-X turns Grok into a white supremacist holocaust denier. I wonder who?!? Jake Tapper and CNN and Politico climax years of political malpractice by exploiting Biden's mental lags and ignoring Trump's total mental breakdown. B-Block (45:40) SPORTSBALLCENTER: Three baseball managers fired in ten days? By the three teams most interested in forcing a lockout and no season in 2027? That's a coincidence. And a second look at the Joe Jackson/Pete Rose decision. C-Block (54:46) THINGS I PROMISED NOT TO TELL: It's graduation season so time to look my graduation and the phone call the Friday before it when I asked the registrar if I WAS graduating and she said "Yes? No?"See omnystudio.com/listener for privacy information.

Former President Joe Biden announced that he has prostate cancer. CNN has the latest news and reaction. Israel agreed to allow a basic amount of aid into Gaza, as it launches a new ground offensive. Meanwhile, the New Yorker’s Ruth Margalit reports that fewer Israeli reservists are showing up for service, because they are exhausted and increasingly skeptical of the government’s claims for continuing the war. There are nearly half a million open manufacturing jobs right now. Greg Rosalsky with NPR explains why the industry is having a hard time filling them. Plus, a tornado devastated Kentucky, what we know about a fertility-clinic bombing in Palm Springs, and how a Mexican navy ship crashed into the Brooklyn Bridge. Today’s episode was hosted by Shumita Basu.

A.M. Edition for May 19. Former President Joe Biden and his family are reviewing treatment options with his doctors, as representatives say the disease has spread to his bones. Plus, Israel says it will start allowing aid into Gaza for the first time in months, as the Israeli military expands its ground operation in the enclave. And Journal foreign correspondent Georgi Kantchev on what to expect from President Trump's phone call with Vladimir Putin today after Russia unleashed a drone barrage on Ukraine. Azhar Sukri hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

On the DSR Daily for Tuesday, we cover Joe Biden's recent diagnisis, JD Vance and Marco Rubio meeting with Pope Leo, talks between Trump, Putin, and Zelensky, and more. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jeff Berwick of @DollarVigilante joins Stew to discuss Biden's Prostate Cancer PsyOp, Trump's Zionist UAE trip and more developments! PATRIOTS WANTED

See omnystudio.com/listener for privacy information.